Rendu Biotechnology

Rendu Biotechnology (仁度生物, 688193.SH) is a Shanghai-listed molecular diagnostics company in Qiming Venture Partners' portfolio, focused on nucleic acid testing products. Per Qiming's 2025 portfolio updates, its SuperSAT fully automated constant-temperature nucleic acid amplification analysis system won NMPA approval that spring , followed by an NMPA-cleared hepatitis B viral DNA assay , and in July 2025 it rushed out a fluorescent-PCR test for chikungunya virus amid a Foshan outbreak — a kit with a 100 copies/mL detection limit and 70-minute amplification time . Elsewhere's corpus covers it mainly through these Qiming weekly briefs, so deeper detail on its founding or financials isn't available here.